Myopia Profile


Five things we know about MiSight 1 day

Posted on March 6th 2023 by Kate Gifford

Sponsored by

CV-Myopia Management_LOGO_PRIMARY.png

In this article:

The MiSight 1 day clinical trial is the longest multisite study in myopia control. Here's what we've learnt a lot along the way.

The MiSight® 1 day clinical trial is the longest-running soft contact lens study among children, and is now reporting seven-year data. With such a valuable longitudinal dataset, many questions have been explored ranging from shorter-term and longer-term efficacy, to tolerance and safety and more. Here's some of what we've learnt along the way.

Seven years of the MiSight 1 day study summarized

The MiSight 1 day clinical trial was conducted in Singapore, the United Kingdom, Portugal and Canada to provide data on an ethnically diverse population, and enrolled children from ages 8 to 12 years who were then followed for seven years.1-3 It can be thought of in three parts.

Part 1: The first three years (years 0-3). The randomized controlled trial saw children aged 8-12 years with myopia -0.75 to -4.00D and no more than -0.75DC of astigmatism fit with either MiSight 1 day or single vision (Proclear® 1 day) CLs. The absolute myopia control effect was 0.73D (59%) less refractive progression and 0.32mm (52%) less axial length growth in the MiSight 1 day group after 3 years, compared to the single vision 1 day lens.1

Part 2: The next three years (years 4-6). The Proclear 1 day single vision wearing children were switched into MiSight® 1 day (T3 group = 3 years of treatment) and the MiSight 1 day wearing children continued (T6 group = 6 years of treatment). In the first three years, the T6 group's axial length grew 0.30mm compared to the T3's (control) groups 0.62mm. In the second three years, both groups showed statistically similar growth of 0.22mm for T6 and 0.18mm for T3. Across Parts 1 and 2, the T3 group's axial length grew by 0.81 ± 0.43mm in total, compared to only 0.49 ± 0.39mm total growth in the T6 group.2

Part 3: The final year (years 6-7). All children were switched from MiSight® 1 day into Proclear 1 day single vision soft contact lenses and monitored for a final year, to assess for any rebound effect. On average, for children aged 8-15 at initiation of treatment, there was no indication that accumulated treatment effect gained following 3 or 6 years of MiSight 1 day wear was lost during a 12-month cessation study. Instead, eye growth reverted to expected, age average myopic progression rates. These outcomes showed no evidence of a rebound effect over 12 months, indicating that myopia control gains are retained.3,4

Figure 2 (left) and Figure 3 (right) from the open access paper by Chamberlain et al (2022), entitled Long-term Effect of Dual-focus Contact Lenses on Myopia Progression in Children: A 6-year Multicenter Clinical Trial.2

Captions are shown below.


FIGURE 2: Mean change from baseline in cycloplegic spherical equivalent refractive error with 95% confidence intervals. Includes only those subjects enrolled in part 2. Unfilled symbols represent subjects in the control intervention, filled symbols represent subjects in the test intervention.

FIGURE 3: Mean change from baseline in axial length with 95% confidence intervals. Includes only those subjects enrolled in part 2. Unfilled symbols represent subjects in the control intervention, filled symbols represent subjects in the test intervention.

#1 The majority of myopic children will respond to MiSight 1 day

There are some important findings here to highlight.2

  1. The majority of children wearing MiSight 1 day responded to treatment, with the data showing that 90% of myopic eyes showed slowing of their myopia progression. This was directly observed in the children whose progression data from three years of Proclear 1 day wear in Part 1 were then compared to their progression while wearing MiSight 1 day for three years in Part 2. There were 10% of MiSight 1 day-wearing eyes which didn't show slowed growth, but this group was too small to undertake further analysis to determine any common factors.
  2. The fastest growing eyes showed the greatest reduction in myopia progression. This finding was revealed by examining the children who were in the control group in Part 1 of the study, who then switched to MiSight 1 day in Part 2. A proportional treatment effect was observed, where the younger and faster-progressing children received the maximum benefit.
  3. Almost one-quarter (23%) of children who wore MiSight 1 day for the full six years did not exhibit any significant refractive progression of their myopia, with -0.25D or less change over six years when their lenses were fitted between the ages of 8 and 12.

90% of myopic eyes in the T3 group showed slowed growth when wearing MiSight 1 day, and around one-quarter of the T6 group showed refractive stability over six years of wear. Myopia progression was slowed 50% on average, in both slow and fast progressors and across age groups.

#2 Visual acuity and visual function are unaffected

The six-year study showed that visual acuity with MiSight 1 day was better than 0.00 logMAR (6/6 or 20/20) at the dispensing and final visits, with no differences between the group who started wear at age 8-12 (6 years of wear: T6) versus the group who started at age 11-15 (3 years of wear: T3).2,5,6 Children aged 8-15 years old wearing MiSight 1 day achieved similar distance and near acuity and subjective vision performance compared to those wearing single vision contact lenses.5,6

A separate study has shown that MiSight 1 day does not influence accommodation or binocular vision function at near.7 This means that MiSight 1 day contact lenses can be expected to function similarly to single vision spectacles or contact lenses at near, for these performance measure.6 Read more in this Case Study entitled Why MiSight 1 day is not a multifocal contact lens.

Visual acuity was 20/20 equivalent in MiSight 1 day wearers with accommodation and binocular vision function unimpacted.

#3 Wearing outcomes were excellent

The MiSight 1 day retention rate was 81% (109 of 135) in Part 1 and 85% (92 of 108) in Part 2, indicating that the majority of children completed the study.1,2 Clinical outcomes aside from myopia control efficacy were as follows.

  • Contact lens wearing time was an average of 6.5 days a week and around 13 hours per day in both groups. The similar wearing patterns for Proclear 1 day and MiSight 1 day groups in the first 3 years of the study suggest that children readily adapted to the dual-focus design as with the single vision lens. Wearing time increased slightly in the second part of the study, by around 1 hour per day in both groups. This indicates that children who had previously worn single vision contact lenses in Part 1 of the study adapted well to dual-focus optics in Part 2. It also shows that children and teenagers are highly compliant with contact lens wearing time when directed to do so. It also indicates that this sort of wearing schedule is required to achieve similar results in clinical practice - full time wear should be encouraged.2
  • No contact lens related serious adverse events (corneal infections, microbial keratitis) were recorded. Daily disposable wear in children aged 8 to 12 who grew up wearing daily disposable lenses full time over 6 years resulted in no significant changes on biomicroscopy (e.g. hypoxia) compared to baseline assessment, with 99% of all slit-lamp observation being grade 1 or less on a 0-4 grading scale.2,8

Children and teens wearing daily disposable lenses demonstrated adherence to the recommended wear times with no changes in ocular health signs over 6 years.

#4 Earlier is better, but you can start later too

At the six-year time point in the study, around half of the children had been wearing MiSight 1 day for the full six years, with the other half having three years of wear, with three years of single vision soft contact lens wear prior. It was found that while starting earlier (age 8-12) is optimal for myopia management, commencing treatment at an older age (11-15 years) could still be beneficial in slowing the rate of myopia progression. These new-to-MiSight 1 day children showed the same progression rate as those who had been wearing MiSight 1 day for three years prior.9

In the second part of the study, 60% of the new-to-MiSight 1 day wearers were teenagers and all were switched from Proclear 1 day single vision contact lenses - with no difference in dropout rates to the first three years, indicating good acceptance. The majority of children previously wearing single vision contact lenses for 3 years successfully adapted to the new optics of MiSight 1 day contact lenses, with 82% completing their sixth year of the study. This means myopia control can be successfully commenced even into the teenage years, and even when prior single vision contact lens wear has taken place.2

Starting MiSight 1 day wear in children ages 8-12 years provides the greatest myopia control effect, but starting in ages 11-15 years provides a benefit too.

#5 Progression is cut by half and benefits are retained

Measurement and modelling of the six-year data indicated that all observed ages of children wearing MiSight 1 day - from 8 to 17 years of age - showed slower myopia progression by approximately 50%.9 The absolute value of that 50% is larger for younger children, who generally are at the time of fastest myopia progression.10,11 This indicates that the greatest impact on eye growth can occur when myopia control treatment with MiSight 1 day is started early and sustained over many years.9

Work presented at the American Academy of Optometry in 2022 indicated no rebound effect in the seventh year of the study, when all children switched from MiSight 1 day to Proclear 1 day single vision soft contact lens wear. Twelve months post-treatment, evidence indicates that no accumulated myopia control benefits were lost following 3 or 6-years of wearing MiSight 1 day. By this time, the study group was aged 16 years or older, and eye growth continued at expected, age-normal rates.3

In all observed ages (8 to 17 years), MiSight 1 day slowed myopia progression by approximately 50%, and treatment effects are sustained after discontinuation from age 16 onwards.

Further reading

FDA Indications for use (US only): MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤0.75 diopters of astigmatism. The lens is to be discarded after each removal.

Availability of interventions with regulatory indications to slow progression of myopia varies by country. CooperVision does not endorse off label prescribing of interventions for myopia control. 

Meet the Authors:

About Kate Gifford

Dr Kate Gifford is an internationally renowned clinician-scientist optometrist and peer educator, and a Visiting Research Fellow at Queensland University of Technology, Brisbane, Australia. She holds a PhD in contact lens optics in myopia, four professional fellowships, over 100 peer reviewed and professional publications, and has presented more than 200 conference lectures. Kate is the Chair of the Clinical Management Guidelines Committee of the International Myopia Institute. In 2016 Kate co-founded Myopia Profile with Dr Paul Gifford; the world-leading educational platform on childhood myopia management. After 13 years of clinical practice ownership, Kate now works full time on Myopia Profile.

About Jeanne Saw

Jeanne is a clinical optometrist based in Sydney, Australia. She has worked as a research assistant with leading vision scientists, and has a keen interest in myopia control and professional education.

As Manager, Professional Affairs and Partnerships, Jeanne works closely with Dr Kate Gifford in developing content and strategy across Myopia Profile's platforms, and in working with industry partners. Jeanne also writes for the CLINICAL domain of, and the My Kids Vision website, our public awareness platform. 

This content is brought to you thanks to unrestricted educational grant from

CV-Myopia Management_LOGO_PRIMARY.png
Back to all articles

Enormous thanks to our visionary sponsors

Myopia Profile’s growth into a world leading platform has been made possible through the support of our visionary sponsors, who share our mission to improve children’s vision care worldwide. Click on their logos to learn about how these companies are innovating and developing resources with us to support you in managing your patients with myopia.